(Q38466329)

3 September 2017

1 reference

title

Exploiting replicative stress to treat cancer (English)

1 reference

3 September 2017

1

1 reference

3 September 2017

author name string

Claus Storgaard Sørensen

series ordinal

2

1 reference

3 September 2017

publication date

8 May 2015

1 reference

Nature Reviews Drug Discovery

3 September 2017

published in

1 reference

3 September 2017

volume

14

1 reference

3 September 2017

issue

6

1 reference

3 September 2017

page(s)

405-423

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd4553

3 September 2017

exact match

0 references

cites work

Maintaining genome stability at the replication fork

1 reference

The DNA-damage response in human biology and disease

31 March 2020

1 reference

Causes and consequences of replication stress

31 March 2020

1 reference

ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage

31 March 2020

1 reference

Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions

31 March 2020

1 reference

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

31 March 2020

1 reference

Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints

31 March 2020

1 reference

Hallmarks of Cancer: The Next Generation

31 March 2020

1 reference

31 March 2020

The Hallmarks of Cancer

1 reference

Oncogene-induced senescence: the bright and dark side of the response

31 March 2020

1 reference

Genomic instability--an evolving hallmark of cancer

31 March 2020

1 reference

Nucleotide deficiency promotes genomic instability in early stages of cancer development

31 March 2020

1 reference

Retinoblastoma pathway defects show differential ability to activate the constitutive DNA damage response in human tumorigenesis

31 March 2020

1 reference

c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability

31 March 2020

1 reference

Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel?

31 March 2020

1 reference

Targeting hypoxia in cancer therapy

31 March 2020

1 reference

Cancer phenotypic lethality, exemplified by the non-essential MTH1 enzyme being required for cancer survival.

31 March 2020

1 reference

Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy

31 March 2020

1 reference

MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool

31 March 2020

1 reference

A switch between DNA polymerases δ and λ promotes error-free bypass of 8-oxo-G lesions

31 March 2020

1 reference

Roles of base excision repair subpathways in correcting oxidized abasic sites in DNA.

31 March 2020

1 reference

Oxygen as a friend and enemy: How to combat the mutational potential of 8-oxo-guanine

31 March 2020

1 reference

Cancer genes and the pathways they control

31 March 2020

1 reference

BRCA1 and BRCA2: different roles in a common pathway of genome protection

31 March 2020

1 reference

BRCA1 is required for postreplication repair after UV-induced DNA damage

31 March 2020

1 reference

Heterozygous mutations in PALB2 cause DNA replication and damage response defects

31 March 2020

1 reference

A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage

31 March 2020

1 reference

A ribonucleotide reductase gene is a transcriptional target of p53 and p73

31 March 2020

1 reference

CDC6: from DNA replication to cell cycle checkpoints and oncogenesis

31 March 2020

1 reference

Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior

31 March 2020

1 reference

Aberrant expression of alternative DNA polymerases: a source of mutator phenotype as well as replicative stress in cancer

31 March 2020

1 reference

A census of amplified and overexpressed human cancer genes

31 March 2020

1 reference

DNA replication stress, genome instability and aging

31 March 2020

1 reference

Balancing repair and tolerance of DNA damage caused by alkylating agents

31 March 2020

1 reference

Cellular processing of platinum anticancer drugs

31 March 2020

1 reference

XRCC3 and Rad51 modulate replication fork progression on damaged vertebrate chromosomes

31 March 2020

1 reference

Y-family DNA polymerases and their role in tolerance of cellular DNA damage.

31 March 2020

1 reference

DNA interstrand crosslink repair and cancer

31 March 2020

1 reference

Repairing DNA-methylation damage

31 March 2020

1 reference

Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity

31 March 2020

1 reference

Visualization of altered replication dynamics after DNA damage in human cells

31 March 2020

1 reference

Nucleoside analogs: molecular mechanisms signaling cell death.

31 March 2020

1 reference

5-Aza-2'-deoxycytidine causes replication lesions that require Fanconi anemia-dependent homologous recombination for repair

31 March 2020

1 reference

5-Fluorouracil: mechanisms of action and clinical strategies

31 March 2020

1 reference

5S ribosomal RNA is an essential component of a nascent ribosomal precursor complex that regulates the Hdm2-p53 checkpoint

31 March 2020

1 reference

Drugging topoisomerases: lessons and challenges

31 March 2020

1 reference

Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase I-DNA complexes

31 March 2020

1 reference

The intra-S-phase checkpoint affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses

31 March 2020

1 reference

Topoisomerase I poisoning results in PARP-mediated replication fork reversal

31 March 2020

1 reference

Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition

31 March 2020

1 reference

Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress

31 March 2020

1 reference

Rad9 protects cells from topoisomerase poison-induced cell death

31 March 2020

1 reference

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

31 March 2020

1 reference

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

31 March 2020

1 reference

The chromatin scaffold protein SAFB1 renders chromatin permissive for DNA damage signaling

31 March 2020

1 reference

Poly(ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activation

31 March 2020

1 reference

Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition

31 March 2020

1 reference

Targeting the checkpoint kinases: chemosensitization versus chemoprotection

31 March 2020

1 reference

Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs

31 March 2020

1 reference

Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage

31 March 2020

1 reference

Chk1 promotes replication fork progression by controlling replication initiation

31 March 2020

1 reference

Claspin, a Chk1-regulatory protein, monitors DNA replication on chromatin independently of RPA, ATR, and Rad17.

31 March 2020

1 reference

Repeated phosphopeptide motifs in Claspin mediate the regulated binding of Chk1

31 March 2020

1 reference

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.

31 March 2020

1 reference

A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial

31 March 2020

1 reference

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.

31 March 2020

1 reference

Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication

31 March 2020

1 reference

ATR phosphorylates SMARCAL1 to prevent replication fork collapse

31 March 2020

1 reference

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.

31 March 2020

1 reference

Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.

31 March 2020

1 reference

Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption.

31 March 2020

1 reference

Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function

31 March 2020

1 reference

Hsp90 phosphorylation, Wee1 and the cell cycle

31 March 2020

1 reference

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

31 March 2020

1 reference

Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover

31 March 2020

1 reference

NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells

31 March 2020

1 reference

Negative regulation of NEDD8 conjugation pathway by novel molecules and agents for anticancer therapy

31 March 2020

1 reference

MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy

31 March 2020

1 reference

Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924.

31 March 2020

1 reference

A gatekeeper residue for NEDD8-activating enzyme inhibition by MLN4924.

31 March 2020

1 reference

Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers

31 March 2020

1 reference

Maternal embryonic leucine zipper kinase is upregulated and required in mammary tumor-initiating cells in vivo

31 March 2020

1 reference

MELK inhibitor, novel molecular targeted therapeutics for human cancer stem cells.

31 March 2020

1 reference

Maternal embryonic leucine zipper kinase (MELK) reduces replication stress in glioblastoma cells

31 March 2020

1 reference

Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer

31 March 2020

1 reference

The crystal structure of MPK38 in complex with OTSSP167, an orally administrative MELK selective inhibitor

31 March 2020

1 reference

The Dbf4-Cdc7 kinase promotes S phase by alleviating an inhibitory activity in Mcm4

31 March 2020

1 reference

Phosphorylation of Mcm2 by Cdc7 promotes pre-replication complex assembly during cell-cycle re-entry

31 March 2020

1 reference

A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity

31 March 2020

1 reference

Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers

31 March 2020

1 reference

Targeting cell division cycle 7 kinase: a new approach for cancer therapy.

31 March 2020

1 reference

Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells

31 March 2020

1 reference

ATR-Chk1-APC/CCdh1-dependent stabilization of Cdc7-ASK (Dbf4) kinase is required for DNA lesion bypass under replication stress

31 March 2020

1 reference

Regulation and roles of Cdc7 kinase under replication stress

31 March 2020

1 reference

Targeting bromodomains: epigenetic readers of lysine acetylation

31 March 2020

1 reference

Selective inhibition of BET bromodomains

31 March 2020

1 reference

BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia.

31 March 2020

1 reference

Anticancer activities of histone deacetylase inhibitors

31 March 2020

1 reference

Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage

31 March 2020

1 reference

H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation

31 March 2020

1 reference

The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy

31 March 2020

1 reference

MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts

31 March 2020

1 reference

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

31 March 2020

1 reference

Nedd8-activating enzyme inhibitor MLN4924 provides synergy with mitomycin C through interactions with ATR, BRCA1/BRCA2, and chromatin dynamics pathways

31 March 2020

1 reference

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

31 March 2020

1 reference

Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours

31 March 2020

1 reference

Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850)

31 March 2020

1 reference

ATR mediates cisplatin resistance in a p53 genotype-specific manner

31 March 2020

1 reference

Inhibition of the Nedd8 system sensitizes cells to DNA interstrand cross-linking agents.

31 March 2020

1 reference

Epigenetic resensitization to platinum in ovarian cancer

31 March 2020

1 reference

Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2.

31 March 2020

1 reference

A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo

31 March 2020

1 reference

DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization

31 March 2020

1 reference

p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage

31 March 2020

1 reference

The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells

31 March 2020

1 reference

A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer

31 March 2020

1 reference

Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress

31 March 2020

1 reference

Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage

31 March 2020

1 reference

Targeting tumour-supportive cellular machineries in anticancer drug development

31 March 2020

1 reference

Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation

31 March 2020

1 reference

Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma.

31 March 2020

1 reference

Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition

31 March 2020

1 reference

Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo

31 March 2020

1 reference

CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.

31 March 2020

1 reference

The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair

31 March 2020

1 reference

Fhit and CHK1 have opposing effects on homologous recombination repair

31 March 2020

1 reference

CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors

31 March 2020

1 reference

CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?

31 March 2020

1 reference

Tumour suppression by p53: a role for the DNA damage response?

31 March 2020

1 reference

Drugging the p53 pathway: understanding the route to clinical efficacy

31 March 2020

1 reference

p53 and E2f: partners in life and death

31 March 2020

1 reference

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

31 March 2020

1 reference

Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy

31 March 2020

1 reference

BRCA1 and Tip60 determine the cellular response to ultraviolet irradiation through distinct pathways

31 March 2020

1 reference

Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors

31 March 2020

1 reference

p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage

31 March 2020

1 reference

Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis

31 March 2020

1 reference

The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage

31 March 2020

1 reference

Endogenous retrovirus drives hitherto unknown proapoptotic p63 isoforms in the male germ line of humans and great apes

31 March 2020

1 reference

Cell cycle kinases as therapeutic targets for cancer

31 March 2020

1 reference

Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells

31 March 2020

1 reference

Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21

31 March 2020

1 reference

Skp2-dependent degradation of p27kip1 is essential for cell cycle progression

31 March 2020

1 reference

Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition

31 March 2020

1 reference

Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer

31 March 2020

1 reference

Tackling the cancer stem cells - what challenges do they pose?

31 March 2020

1 reference

MYC regulation of CHK1 and CHK2 promotes radioresistance in a stem cell-like population of nasopharyngeal carcinoma cells

31 March 2020

1 reference

Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells

31 March 2020

1 reference

RNF4 and PLK1 are required for replication fork collapse in ATR-deficient cells

31 March 2020

1 reference

DNA repair pathways as targets for cancer therapy

31 March 2020

1 reference

Timeline: Chemotherapy and the war on cancer.

31 March 2020

1 reference

Myelodysplastic syndromes: the complexity of stem-cell diseases

31 March 2020

1 reference

Break-induced replication repair of damaged forks induces genomic duplications in human cells.

31 March 2020

1 reference

An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells

31 March 2020

1 reference

p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy

31 March 2020

1 reference

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

31 March 2020

1 reference

The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis

31 March 2020

1 reference

The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways

31 March 2020

1 reference

Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A.

31 March 2020

1 reference

Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells

31 March 2020

1 reference

The radioresistance to killing of A1-5 cells derives from activation of the Chk1 pathway

31 March 2020

1 reference

Control of the G2/M checkpoints after exposure to low doses of ionising radiation: implications for hyper-radiosensitivity

31 March 2020

1 reference

In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma

31 March 2020

1 reference

Homologous recombination repairs secondary replication induced DNA double-strand breaks after ionizing radiation.

31 March 2020

1 reference

Preoperative versus postoperative chemoradiotherapy for rectal cancer

31 March 2020

1 reference

Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years

31 March 2020

1 reference

The history of Toll-like receptors - redefining innate immunity.

31 March 2020

1 reference

The blockade of immune checkpoints in cancer immunotherapy

31 March 2020

1 reference

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

31 March 2020

1 reference

Many faces of DAMPs in cancer therapy

31 March 2020

1 reference

Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors

31 March 2020

1 reference

Mechanisms governing metastatic dormancy and reactivation

31 March 2020

1 reference

Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs

31 March 2020

1 reference

A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy

31 March 2020

1 reference

Prospective therapeutic applications of p53 inhibitors

31 March 2020

1 reference

An APC/C inhibitor stabilizes cyclin B1 by prematurely terminating ubiquitination

31 March 2020

1 reference

Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins.

31 March 2020

1 reference

Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins

31 March 2020

1 reference

Molecular pathways: reactive oxygen species homeostasis in cancer cells and implications for cancer therapy

31 March 2020

1 reference

Association of reactive oxygen species levels and radioresistance in cancer stem cells

31 March 2020

1 reference

Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

31 March 2020

1 reference

The antioxidant function of the p53 tumor suppressor

31 March 2020

1 reference

Phase I and clinical pharmacological evaluation of aphidicolin glycinate

31 March 2020

1 reference

Identification of proteins at active, stalled, and collapsed replication forks using isolation of proteins on nascent DNA (iPOND) coupled with mass spectrometry.

31 March 2020

1 reference

A proteomic characterization of factors enriched at nascent DNA molecules

31 March 2020

1 reference

Nascent chromatin capture proteomics determines chromatin dynamics during DNA replication and identifies unknown fork components

31 March 2020

1 reference

Enzymatic removal of ribonucleotides from DNA is essential for mammalian genome integrity and development.

31 March 2020

1 reference

DNA polymerases and cancer.

31 March 2020

1 reference

Translesion DNA synthesis in the context of cancer research

31 March 2020

1 reference

Replication licensing and cancer--a fatal entanglement?

31 March 2020

1 reference

Transcription-replication encounters, consequences and genomic instability

31 March 2020

1 reference

Collisions between replication and transcription complexes cause common fragile site instability at the longest human genes

31 March 2020

1 reference

Identification of early replicating fragile sites that contribute to genome instability

31 March 2020

1 reference

How telomeres are replicated

31 March 2020

1 reference

The histone methyltransferase SET8 is required for S-phase progression

31 March 2020

1 reference

The histone H4 Lys 20 methyltransferase PR-Set7 regulates replication origins in mammalian cells.

31 March 2020

1 reference

SET8 is degraded via PCNA-coupled CRL4(CDT2) ubiquitylation in S phase and after UV irradiation

31 March 2020

1 reference

CRL4(Cdt2)-mediated destruction of the histone methyltransferase Set8 prevents premature chromatin compaction in S phase

31 March 2020

1 reference

CRL4(Cdt2) regulates cell proliferation and histone gene expression by targeting PR-Set7/Set8 for degradation

31 March 2020

1 reference

PRP19 transforms into a sensor of RPA-ssDNA after DNA damage and drives ATR activation via a ubiquitin-mediated circuitry

31 March 2020

1 reference

A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex

31 March 2020

1 reference

Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening

31 March 2020

1 reference

RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells

31 March 2020

1 reference

Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice.

31 March 2020

1 reference

Targeting homologous recombination repair defects in cancer

31 March 2020

1 reference

PARP inhibition: PARP1 and beyond

31 March 2020

1 reference

Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase.

31 March 2020

1 reference

Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair.

31 March 2020

1 reference

The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA

31 March 2020

1 reference

PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints

31 March 2020

1 reference

Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction.

31 March 2020

1 reference

Regulation of p73 activity by post-translational modifications

31 March 2020

1 reference

p38 MAPK/MK2-mediated induction of miR-34c following DNA damage prevents Myc-dependent DNA replication

31 March 2020

1 reference

DNA replication arrest in response to genotoxic stress provokes early activation of stress-activated protein kinases (SAPK/JNK).

31 March 2020

1 reference

The IKK NF-kappa B system: a treasure trove for drug development

31 March 2020

1 reference

Exploiting the PI3K/AKT pathway for cancer drug discovery

31 March 2020

1 reference

Targeting IAP proteins for therapeutic intervention in cancer

31 March 2020

1 reference

Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics

31 March 2020

1 reference

Mitochondrial rhomboid PARL regulates cytochrome c release during apoptosis via OPA1-dependent cristae remodeling

31 March 2020

1 reference

OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion

31 March 2020

1 reference

Marine natural product aurilide activates the OPA1-mediated apoptosis by binding to prohibitin

31 March 2020

1 reference

Alkylating DNA damage stimulates a regulated form of necrotic cell death

31 March 2020

1 reference

Senescence, apoptosis and therapy--cutting the lifelines of cancer.

31 March 2020

1 reference

Portrait of replication stress viewed from telomeres

31 March 2020

1 reference

Increased telomere fragility and fusions resulting from TRF1 deficiency lead to degenerative pathologies and increased cancer in mice

31 March 2020

1 reference

ATR suppresses telomere fragility and recombination but is dispensable for elongation of short telomeres by telomerase

31 March 2020

1 reference

RNAi screening comes of age: improved techniques and complementary approaches

31 March 2020

1 reference

Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening

31 March 2020

1 reference

A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability

31 March 2020

1 reference

High-throughput siRNA screens using γH2AX as marker uncover key regulators of genome integrity in mammalian cells.

31 March 2020

1 reference

Depletion of RAD17 sensitizes pancreatic cancer cells to gemcitabine.

31 March 2020

1 reference

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer

31 March 2020

1 reference

Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance

31 March 2020

1 reference

A genome-wide screen identifies p97 as an essential regulator of DNA damage-dependent CDT1 destruction.

31 March 2020

1 reference

RNAi-based screening identifies the Mms22L-Nfkbil2 complex as a novel regulator of DNA replication in human cells

31 March 2020

1 reference

An extra allele of Chk1 limits oncogene-induced replicative stress and promotes transformation

31 March 2020

1 reference

Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR

31 March 2020

1 reference

A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging

31 March 2020

1 reference

Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors

31 March 2020

1 reference

Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.

31 March 2020

1 reference

31 March 2020

Cancer genome landscapes

1 reference

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

31 March 2020

1 reference

Systematic identification of genomic markers of drug sensitivity in cancer cells

31 March 2020

1 reference

Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance

31 March 2020

1 reference

Replication stress links structural and numerical cancer chromosomal instability

31 March 2020

1 reference

Patient-derived tumour xenografts as models for oncology drug development

31 March 2020

1 reference

Defining replication origin efficiency using DNA fiber assays

31 March 2020

1 reference

Autoradiography of chromosomal DNA fibers from Chinese hamster cells

31 March 2020

1 reference

Replicon clusters are stable units of chromosome structure: evidence that nuclear organization contributes to the efficient activation and propagation of S phase in human cells

31 March 2020

1 reference

Dynamic molecular combing: stretching the whole human genome for high-resolution studies.

31 March 2020

1 reference

Chk1 requirement for high global rates of replication fork progression during normal vertebrate S phase

31 March 2020

1 reference

A rapid and efficient method to purify proteins at replication forks under native conditions.

31 March 2020

1 reference

Monitoring the spatiotemporal dynamics of proteins at replication forks and in assembled chromatin using isolation of proteins on nascent DNA.

31 March 2020

1 reference

Analysis of protein dynamics at active, stalled, and collapsed replication forks.

31 March 2020

1 reference

Replication protein A and the Mre11.Rad50.Nbs1 complex co-localize and interact at sites of stalled replication forks

31 March 2020

1 reference

Pathways of mammalian replication fork restart.

31 March 2020

1 reference

Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair.

31 March 2020

1 reference

Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1

31 March 2020

1 reference

PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination.

31 March 2020

1 reference

Repriming of DNA synthesis at stalled replication forks by human PrimPol

31 March 2020

1 reference

PrimPol bypasses UV photoproducts during eukaryotic chromosomal DNA replication

31 March 2020

1 reference

Rescue of replication failure by Fanconi anaemia proteins

31 March 2020

1 reference

Histone chaperone activity of Fanconi anemia proteins, FANCD2 and FANCI, is required for DNA crosslink repair

31 March 2020

1 reference

FANCD2 binds CtIP and regulates DNA-end resection during DNA interstrand crosslink repair.

31 March 2020

1 reference

Excess Mcm2-7 license dormant origins of replication that can be used under conditions of replicative stress.

31 March 2020

1 reference

Dormant origins licensed by excess Mcm2-7 are required for human cells to survive replicative stress.

31 March 2020

1 reference

How dormant origins promote complete genome replication

31 March 2020

1 reference

Controlling DNA replication origins in response to DNA damage - inhibit globally, activate locally

31 March 2020

1 reference

Diminished origin-licensing capacity specifically sensitizes tumor cells to replication stress.

31 March 2020

1 reference

ATR prohibits replication catastrophe by preventing global exhaustion of RPA.

31 March 2020

1 reference

Single- and double-stranded DNA: building a trigger of ATR-mediated DNA damage response

31 March 2020

1 reference

ATR: an essential regulator of genome integrity

31 March 2020

1 reference

ATR signaling at a glance

31 March 2020

1 reference

Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid

31 March 2020

1 reference

Genetical Implications of the Structure of Deoxyribonucleic Acid

31 March 2020

2 references

31 March 2020

12 December 2020

Fluorinated pyrimidines, a new class of tumour-inhibitory compounds

1 reference

INHIBITION OF CELL DIVISION IN ESCHERICHIA COLI BY ELECTROLYSIS PRODUCTS FROM A PLATINUM ELECTRODE

31 March 2020

1 reference

Cis-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular Cancer

31 March 2020

1 reference

A checkpoint regulates the rate of progression through S phase in S. cerevisiae in response to DNA damage.

31 March 2020

1 reference

cDNA cloning and gene mapping of a candidate human cell cycle checkpoint protein

31 March 2020

1 reference

Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25

31 March 2020

1 reference

Atm-dependent interactions of a mammalian chk1 homolog with meiotic chromosomes

31 March 2020

1 reference

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

31 March 2020

1 reference

A history of cancer chemotherapy

31 March 2020

1 reference

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

31 March 2020

1 reference

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

31 March 2020

1 reference

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

31 March 2020

1 reference

Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.

31 March 2020

1 reference

Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.

31 March 2020

1 reference

Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity

31 March 2020

1 reference

Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

31 March 2020

1 reference

Inhibition of cisplatin-induced ATR activity and enhanced sensitivity to cisplatin

31 March 2020

1 reference

12 December 2020

p53-induced p21 controls DNA replication

1 reference

12 December 2020

Action of 9-beta-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism

1 reference

12 December 2020

Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells

1 reference

12 December 2020

Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine

1 reference

12 December 2020

Dormancy in breast cancer

1 reference

12 December 2020

Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase

1 reference

12 December 2020

Wee1 kinase as a target for cancer therapy

1 reference

12 December 2020

Gemcitabine--a safety review

1 reference

12 December 2020

Gemcitabine: preclinical pharmacology and mechanisms of action.

1 reference

12 December 2020

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD4553

1 reference

3 September 2017

1 reference